share_log

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K：重大事件
美股sec公告 ·  06/07 17:03
Moomoo AI 已提取核心訊息
On June 6, 2024, Christopher Towers resigned from his position as a member of the Board of Directors and from his roles in the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee at Intelligent Bio Solutions Inc., effective June 7, 2024. Towers, who was serving as the Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, did not resign due to any disagreements with the company's operations, policies, or practices. Following his departure, Nicola Fraser was appointed to the Board and as the new Chair of the Audit Committee on June 7, 2024. Fraser, 48, is the Managing Partner of NextKey Services LLC and has a background in financial leadership roles at JP Morgan Chase, Fannie Mae, and Deloitte...Show More
On June 6, 2024, Christopher Towers resigned from his position as a member of the Board of Directors and from his roles in the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee at Intelligent Bio Solutions Inc., effective June 7, 2024. Towers, who was serving as the Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, did not resign due to any disagreements with the company's operations, policies, or practices. Following his departure, Nicola Fraser was appointed to the Board and as the new Chair of the Audit Committee on June 7, 2024. Fraser, 48, is the Managing Partner of NextKey Services LLC and has a background in financial leadership roles at JP Morgan Chase, Fannie Mae, and Deloitte. She is an active CPA and holds a CGMA designation. The Board has confirmed Fraser's independence according to Nasdaq rules. Additionally, Steven Boyages was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee, also taking on the role of Chair for the latter. The Board's committee structure has been updated accordingly.
2024年6月6日，克里斯托弗·塔爾斯辭去了在智聯生物解決方案公司董事會的職務以及審計委員會，薪酬委員會和提名和董事會治理委員會的職務，辭職時間爲2024年6月7日。塔爾斯曾擔任審計委員會和提名和董事會治理委員會的主席，他辭職並非由於與公司的運營、政策或實踐存在任何分歧。在他離職後，尼古拉·弗雷澤於2024年6月7日被任命爲董事會成員並擔任審計委員會的新主席。弗雷澤，48歲，是NextKey Services LLC的管理合夥人，在JP Morgan Chase，Fannie Mae和Deloitte擔任過財務領導角色。她是一名執業註冊會計師，並持有CGMA資格認證。董事會已根據納斯達克規則確認了弗雷澤的獨立性。此外，史蒂文·博亞吉斯被任命爲薪酬委員會和提名和董事會治理委員會成員，並擔任後者的主席。董事會的委員會結構已相應更新。
2024年6月6日，克里斯托弗·塔爾斯辭去了在智聯生物解決方案公司董事會的職務以及審計委員會，薪酬委員會和提名和董事會治理委員會的職務，辭職時間爲2024年6月7日。塔爾斯曾擔任審計委員會和提名和董事會治理委員會的主席，他辭職並非由於與公司的運營、政策或實踐存在任何分歧。在他離職後，尼古拉·弗雷澤於2024年6月7日被任命爲董事會成員並擔任審計委員會的新主席。弗雷澤，48歲，是NextKey Services LLC的管理合夥人，在JP Morgan Chase，Fannie Mae和Deloitte擔任過財務領導角色。她是一名執業註冊會計師，並持有CGMA資格認證。董事會已根據納斯達克規則確認了弗雷澤的獨立性。此外，史蒂文·博亞吉斯被任命爲薪酬委員會和提名和董事會治理委員會成員，並擔任後者的主席。董事會的委員會結構已相應更新。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息